62749-46-6

Basic information

• Product Name: AMRINONE RELATED COMPOUND A (100 MG) (5-CARBOXAMIDE[3,4'-BIPYRIDIN]-6(1H)-ONE)
• Synonyms: AMRINONE RELATED COMPOUND A (100 MG) (5-CARBOXAMIDE[3,4'-BIPYRIDIN]-6(1H)-ONE);1,6-dihydro-6-oxo[3,4'-bipyridine]-5-carboxamide;5-CarboxaMide-[3,4'-bipyridin]-6(1H)-one;AMrinone Related CoMpound A;Amrinone Related Compound A (100 mg) (5-carboxamide[3,4'-bipyridin]-6(1H)-one) (Inamrinone Related Compound A);2-oxo-5-pyridin-4-yl-1H-pyridine-3-carboxamide
• CAS NO: 62749-46-6
• Molecular Formula: C₁₁H₉N₃O₂
• Molecular Weight: 215.20806
• EINECS: 263-714-3
• Product Categories: Inhibitors, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 62749-46-6.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: AMRINONE RELATED COMPOUND A (100 MG) (5-CARBOXAMIDE[3,4'-BIPYRIDIN]-6(1H)-ONE)(CAS DataBase Reference)
• NIST Chemistry Reference: AMRINONE RELATED COMPOUND A (100 MG) (5-CARBOXAMIDE[3,4'-BIPYRIDIN]-6(1H)-ONE)(62749-46-6)
• EPA Substance Registry System: AMRINONE RELATED COMPOUND A (100 MG) (5-CARBOXAMIDE[3,4'-BIPYRIDIN]-6(1H)-ONE)(62749-46-6)

Safety Data

• Hazardous Substances Data: 62749-46-6(Hazardous Substances Data)

Usage

Description

AMRINONE RELATED COMPOUND A (100 MG) (5-CARBOXAMIDE[3,4'-BIPYRIDIN]-6(1H)-ONE) is a chemical compound that serves as an intermediate in the synthesis of the cardiac agent Amrinone (A635000). AMRINONE RELATED COMPOUND A (100 MG) (5-CARBOXAMIDE[3,4'-BIPYRIDIN]-6(1H)-ONE) is characterized by its unique structure, which includes a 5-carboxamide group attached to a bipyridin ring system, and plays a crucial role in the development of pharmaceuticals for cardiovascular applications.

Uses

Used in Pharmaceutical Industry:
AMRINONE RELATED COMPOUND A (100 MG) (5-CARBOXAMIDE[3,4'-BIPYRIDIN]-6(1H)-ONE) is used as a key intermediate in the synthesis of the cardiac agent, Amrinone (A635000), for its therapeutic effects on heart conditions.
Used in Cardiology:
AMRINONE RELATED COMPOUND A (100 MG) (5-CARBOXAMIDE[3,4'-BIPYRIDIN]-6(1H)-ONE) is utilized in the preparation of Amrinone (A635000), a medication that helps improve cardiac function by increasing the force of heart contractions and promoting vasodilation, thus providing relief to patients with heart failure or other related conditions.

Upstream product

• 108-13-4 malonodiamide 
• 26866-49-9 α-(4-pyridinyl)-β-(dimethylamino)acrolein 
• 78448-41-6 hydrochloride of N,N-dimethyl-N-<3-dimethylamino-2-(pyrid-4'-yl)prop-2-enylidene>ammonium chloride 
• 51076-46-1 2-(4-pyridyl)-propan-1,3-dione 
• 62749-26-2 3-cyano-5-(pyridin-4-yl)-(1H)-pyridin-2-one 
• 80645-64-3 1-(N,N-Dimethylamino)-3-(N,N-dimethyl)-2-(pyrid-4-yl)-prop-1-en-chlorid-hydrochlorid 
• 107-91-5 cyanoacetic acid amide 

Downstream Products

• 62749-47-7 N-Acetylamrinone 
• 60719-84-8 amrinone 

Relevant articles and documents

An improved synthesis of amrinone by phase-transfer catalysis

-

Process for preparing 5 pyridyl pyridine-2 (1H)-ones

5-Pyridinyl-6-R2 -3-R1 -2(1H)-pyridinones (I), where R2 is hydrogen or lower alkyl and R1 is a cyano, a carbamoyl or an amino group are prepared: by reaction of 1-R2 -1-oxo-2-pyridinyl-3-dialkylaminopropane (II) with malonamide under solid-liquid or liquid-liquid phase transfer catalysis conditions to obtain 1,2-dihydro-2-oxo-6-R2 -5-pyridinylnicotinamide (IV), or by reaction of II with cyanoacetamide under solid-liquid or liquid-liquid phase transfer catalysis conditions to obtain 1,2-dihydro-2-oxo-6-R2 -5-pyridinylnicotinonitrile (III) and partially hydrolizing III to yield IV; finally the carbamoyl group of IV is converted to amino and 1,2-dihydro-2-oxo-6-R2 -5-pyridinyl-3-aminopyridin-2-one are obtained.

3-Amino-5-(pyridinyl)-2(1H)-pyridinones

Compounds useful as cardiotonic agents are 1-R-3-Q-5-PY-2(1H)-pyridinones (I) where R is hydrogen, lower-alkyl or lower-hydroxyalkyl, Q is amino (preferred), lower-alkylamino, di-(lower-alkyl)amino or NHAc, Ac is lower-alkanoyl or lower-carbalkoxy, and PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents. The corresponding compounds where Q is nitro, carbamyl, cyano, halo or hydrogen are useful as intermediates and those where Q is hydrogen or cyano also are useful as cardiotonic agents. Said compounds are prepared: by reacting α-PY-β-(R1 R2 N)acrolein (II) with malonamide to produce 1,2-dihydro-2-oxo-5-PY-nicotinamide (Ia) and reacting Ia with a reagent capable of converting carbamyl to amino to produce 3-amino-5-PY-2(1H)-pyridinone (Ib); by reacting II or α-PY-malonaldehyde (II') with α-cyanoacetamide to produce 1,2-dihydro-2-oxo-5-PY-nicotinonitrile (III) and partially hydrolyzing III to produce Ia; and, by heating 1,2-dihydro-2-oxo-5-PY-nicotinic acid (IV) with a mixture of concentrated sulfuric acid and concentrated nitric acid to produce 3-nitro-5-PY-2(1H)-pyridinone (Ic) and then either reducing Ic to produce Ib or first reacting Ic with an alkylating agent to produce 1-R'-3-nitro-5-PY-2(1H)-pyridinone (Id) and reducing Id to produce 1-R'-3-amino-5-PY-2(1H)-pyridinone (Ib) where R' is lower-alkyl or lower-hydroxyalkyl. Other derivatives of I where Q is amino are shown.